Tirzepatide is a dual GIP and GLP-1 receptor agonist engineered as a single peptide — mechanism, trial data, and the clinical record.

The short version

Tirzepatide is a prescription medicine approved by the FDA for type 2 diabetes (May 2022), obesity (November 2023), and obstructive sleep apnea. It is a synthetic peptide — 39 amino acids long — that was engineered to activate two separate hormone receptors in the gut and pancreas at once: the GIP receptor and the GLP-1 receptor. Both receptors are normally activated after a meal to help the body manage blood sugar. By hitting both at the same time with a single molecule, tirzepatide produces larger blood-sugar reductions and greater weight loss than drugs that activate only the GLP-1 receptor. In a large phase 3 trial (SURMOUNT-1, 2539 participants), the 15 mg dose reduced body weight by an average of 20.9% over 72 weeks ^[4]. The most common side effects are nausea and other gastrointestinal symptoms, especially during dose increases. What people report — including the downsides — is covered on the effects page. This site documents the published clinical and mechanistic record on tirzepatide — peer-reviewed findings, sourced and cited.

Tirzepatide peptide: structure and receptor targets

Tirzepatide (INN; also known as LY3298176) is a 39-amino-acid synthetic peptide — a tirzepatide peptide built on the backbone of native GIP (glucose-dependent insulinotropic polypeptide, an incretin hormone released from the gut after eating). A C20 fatty diacid arm attached via a glutamic acid linker and two aminoethoxy linker units gives it high albumin affinity, extending its half-life to approximately five days and supporting once-weekly subcutaneous dosing ^[1]. Molecular formula: C225H348N48O68. Molecular weight: 4813.53 Da. CAS: 2023788-19-2. ATC code: A10BX16.

The two primary receptor targets are the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). Both are G-protein-coupled receptors expressed across the pancreas, central nervous system, adipose tissue, liver, and heart. The GIP receptor drives glucose-dependent insulin secretion and influences fat metabolism; the GLP-1 receptor drives insulin secretion, suppresses glucagon (the hormone that raises blood sugar), slows gastric emptying, and reduces appetite. Engaging both with a single molecule is the engineering premise of tirzepatide ^[1].

In vitro signalling assays showed tirzepatide is an imbalanced dual agonist: it engages the GIP receptor more fully than the GLP-1 receptor, and it shows biased GLP-1 receptor signalling that favours cyclic AMP (cAMP — an intracellular messenger that boosts insulin secretion) over beta-arrestin recruitment (a pathway that internalises the receptor and limits its activity) ^[2]. In primary human islet experiments, blocking the GIP receptor with an antagonist consistently reduced tirzepatide-stimulated insulin secretion — confirming that both receptors contribute meaningfully to its insulinotropic effect in human tissue ^[11].

Tirzepatide results: what the SURPASS and SURMOUNT trials measured

The SURPASS programme evaluated tirzepatide in type 2 diabetes (T2DM). In SURPASS-2 — an open-label 40-week phase 3 trial in 1879 adults with T2DM — once-weekly tirzepatide at 5, 10, and 15 mg reduced glycated haemoglobin (HbA1c, a blood marker of average glucose over roughly three months) by 2.01, 2.24, and 2.30 percentage points respectively, versus 1.86 percentage points with the comparator — superior at all three doses ^[3]. Body-weight reductions were also greater with tirzepatide ^[3].

The SURMOUNT programme evaluated tirzepatide in obesity. In SURMOUNT-1 — a 72-week phase 3 double-blind RCT in 2539 adults with obesity (BMI ≥30, or ≥27 with a weight-related complication) and without diabetes — once-weekly tirzepatide produced mean weight changes of -15.0% (5 mg), -19.5% (10 mg), and -20.9% (15 mg) versus -3.1% with placebo ^[4]. In SURMOUNT-5 — a 72-week head-to-head phase 3b RCT in 751 adults with obesity but without T2DM — tirzepatide produced a mean weight change of -20.2% versus -13.7% with the comparator (p<0.001), with higher proportions reaching ≥10%, ≥15%, and ≥20% weight reduction ^[5].

A meta-analysis of 6 RCTs (6,579 participants) confirmed dose-response effects on HbA1c (weighted mean difference -1.07 percentage points versus controls) and body weight (weighted mean difference -7.99 kg), without a significant increase in hypoglycaemia risk as monotherapy ^[12]. See full Tirzepatide research for the complete trial roster.

Tirzepatide vs semaglutide: what the head-to-head data shows

Two large randomised trials have compared tirzepatide with semaglutide directly. In SURPASS-2 (1879 adults with T2DM, 40 weeks), tirzepatide was superior to semaglutide 1 mg on HbA1c reduction at all three doses, with body-weight treatment differences of -1.9, -3.6, and -5.5 kg ^[3]. In SURMOUNT-5 (751 adults with obesity, without T2DM, 72 weeks), tirzepatide reduced body weight by -20.2% versus -13.7% with semaglutide (p<0.001), with greater reductions in waist circumference and higher proportions reaching every weight-loss threshold tested ^[5].

An indirect comparison (adjusted ML-NMR analysis, 2026) versus oral semaglutide 50 mg found tirzepatide 10 mg produced a weight difference of -4.48% (95% CI -6.35 to -2.61) and tirzepatide 15 mg a difference of -5.59% (-7.52 to -3.77), with comparable safety profiles ^[13].

Regulatory and safety summary

Tirzepatide is FDA-approved. Approved indications: type 2 diabetes mellitus (May 2022); chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27 with a weight-related complication) (November 2023); moderate-to-severe obstructive sleep apnea in adults with obesity ^[7]. It is not approved for type 1 diabetes.

The prescribing information carries a boxed warning: in rodent studies, structurally related incretin drugs caused dose- and duration-dependent thyroid C-cell tumours. Whether this risk applies to humans is not established. The label states tirzepatide should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 ^[15]. The most common adverse events across trials were gastrointestinal — nausea, diarrhoea, vomiting, constipation — mostly mild to moderate and most frequent during dose escalation. A meta-analysis of 9 RCTs (9,871 participants) found no significant increase in pancreatitis risk but a significant increase in the composite gallbladder or biliary disease endpoint (RR 1.97, 95% CI 1.14-3.42) versus controls ^[6]. Full safety detail is on Tirzepatide effects.